National Cancer Institute; Notice of Meeting, 76836-76837 [2023-24578]
Download as PDF
<![CDATA[
76836
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel RFA–
OD–23–013 and RFA–OD–23–014—
Understanding Chronic Conditions
Understudied Among Women Special
Emphasis Panel (SEP), November 20,
2023, 10:00 a.m. to November 21, 2023,
06:30 p.m., National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD, 20892 which was
published in the Federal Register on
October 27, 2023, 88 FR 73865 Doc
2023–23748
This meeting is being amended to
change the Panel name to Center for
Scientific Review Special Emphasis
Panel RFA–OD–23–013 and RFA–OD–
23–014—Understanding Chronic
Conditions Understudied Among
Women. The meeting is closed to the
public.
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–24579 Filed 11–6–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Amy F. Petrik, Ph.D. at 240–627–3721
or amy.petrik@nih.gov. Licensing
information may be obtained by
communicating with the indicated
licensing contact at the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:30 Nov 06, 2023
Jkt 262001
Rockville, MD, 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
Base-Covered HIV–1 Envelope
Ectodomains and Their Use
Description of Technology:
Researchers at the Vaccine Research
Center (‘‘VRC’’) of the National Institute
of Allergy and Infectious Diseases
(‘‘NAID’’) continue to pursue a safe and
effective HIV–1 vaccine to combat the
HIV–1/AIDS pandemic.
To this end, researchers have
engineered the soluble HIV–1
ectodomain trimer so that it is stabilized
in its prefusion conformation by
artificial disulfides, helix-disrupting
prolines, and other structure-based
alterations. However, mice and nonhuman primates immunized with these
engineered soluble HIV–1 trimers
produced a significant (>90% in some
cases) immune response to the exposed
trimer base.
VRC researchers further modified the
engineered prefusion soluble HIV–1
trimers by adding N-linked glycans to
specific sites on the protein’s base to
block this immunodominant surface.
They found that these N-linked glycans
did reduce production of nonneutralizing antibodies directed to the
trimer base. These soluble, glycanmasked prefusion HIV–1 trimers are
envisioned as being a part of a
heterologous prime-boost vaccine
regimen.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Vaccine for prevention of HIV–1
infection
• Therapeutic vaccine for treatment of
HIV–1 infection
Competitive Advantages:
• Currently, no licensed HIV vaccine
exists
Development Stage:
• Animal studies
Inventors: Peter Kwong, John Mascola,
Tongqing Zhou, Adam Olia, Reda Rawi,
Yongping Yang, Cheng Cheng (all of
NIAID).
Publications: Olia, et al. (2023)
Soluble prefusion-closed HIV-envelope
trimers with glycan-covered bases.
iScience 26, 107403, August 18, 2023.
DOI: https://doi.org/10.1016/
j.sci.2023.107403.
PO 00000
Frm 00118
Fmt 4703
Sfmt 4703
Intellectual Property: HHS Reference
Number E–079–2022 includes PCT
Patent Application No. PCT/US2023/
065009 filed on March 27, 2023.
Licensing Contact: To license this
technology, please contact Amy F.
Petrik, Ph.D., 240–627–3721;
amy.petrik@nih.gov, and reference E–
079–2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–24551 Filed 11–6–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual
meeting and is open to the public as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting
should notify the Contact Person listed
below in advance of the meeting. The
meeting can be accessed from the NIH
Videocast at the following link: https://
videocast.nih.gov/.
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Date: February 8, 2024.
Open: 11:00 a.m. to 1:05 p.m.
Agenda: NCAB Subcommittee Meetings.
Open: 1:15 p.m. to 3:30 p.m.
Agenda: Director’s and Program reports
and presentations; business of the Board.
Closed: 3:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Bethesda,
MD 20892 (Virtual Meeting).
E:\FR\FM\07NON1.SGM
07NON1
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm, where an agenda,
instructions for accessing the virtual NCAB
meetings, and any additional information for
the meetings will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–24578 Filed 11–6–23; 8:45 am]
BILLING CODE 4140–01–P
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Contact Person: Christopher D. Kane,
Ph.D., Health Science Administrator and
Program Officer, Office of Scientific
Operations, NCI at Frederick, National
Cancer Institute, National Institutes of
Health, 1050 Boyles Street, Building 427,
Room 4, Frederick, Maryland 21702,
christopher.kane@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: FNLAC:
https://deainfo.nci.nih.gov/advisory/fac/
fac.htm, where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2023–24584 Filed 11–6–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Meeting
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
The meeting will be held virtually
and is open to the public. Individuals
who plan to view the virtual meeting
and need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The meeting will be videocast
and can be accessed from the NIH
Videocasting and Podcasting website
(https://videocast.nih.gov).
Name of Committee: Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
Date: February 29, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: Ongoing and new activities at the
Frederick National Laboratory for Cancer
Research.
VerDate Sep<11>2014
16:30 Nov 06, 2023
Jkt 262001
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or
peter.tung@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
Technology Transfer and Intellectual
SUMMARY:
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
76837
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Beta Globin Mimetic Peptides and
Their Use
Description of Technology: Feedback
vasodilation by endothelium-derived
nitric oxide (NO) is under the regulation
of globins. Inventors discovered that not
only the alpha globin but also the beta
globin subunits of hemoglobin are
expressed in the human artery wall,
with beta globin interacting directly
with endothelium-derived nitric oxide
synthase (eNOS). This discovery of
tetrameric hemoglobin binding to eNOS
has led inventors to develop novel
mimetic peptides that disrupt the
binding of beta globin to eNOS,
diminishing the ability of hemoglobin to
restrict NO release and thereby
enhancing NO-mediated feedback
vasodilation. These agents can be used
to increase NO signaling from
endothelial cells and thus inhibit,
prevent, or reverse vasoconstriction.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Novel peptides to treat vascular
diseases characterized by
vasoconstriction, excess alpha
adrenergic signaling, or insufficient
nitric oxide signaling. Applications
could range from cerebral vasospasm to
pulmonary hypertension, to chronic
kidney disease, to transfusion medicine,
to erectile dysfunction, and to exercise
physiology.
Competitive Advantages:
• New pathway for regulation of
vasoconstriction/vasodilation that is
separate from the pathways that current
products available for treating nitric
oxide deficiency target. Combination
therapy with current vasoconstriction/
vasodilation medications of different
mechanisms may be possible.
• Enhancement of NO release at the
junction between the endothelial cell
and smooth muscle cell may provide
greater potency and fewer off-target
effects than other forms of NO delivery.
Development Stage:
• Peptides have been tested in human
and canine arteries ex vivo.
E:\FR\FM\07NON1.SGM
07NON1
]]>Agencies
[Federal Register Volume 88, Number 214 (Tuesday, November 7, 2023)]
[Notices]
[Pages 76836-76837]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24578]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual meeting and is open to the
public as indicated below. Individuals who plan to view the virtual
meeting and need special assistance or other reasonable accommodations
to view the meeting should notify the Contact Person listed below in
advance of the meeting. The meeting can be accessed from the NIH
Videocast at the following link: https://videocast.nih.gov/.
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Date: February 8, 2024.
Open: 11:00 a.m. to 1:05 p.m.
Agenda: NCAB Subcommittee Meetings.
Open: 1:15 p.m. to 3:30 p.m.
Agenda: Director's and Program reports and presentations;
business of the Board.
Closed: 3:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Bethesda, MD 20892 (Virtual Meeting).
[[Page 76837]]
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm, where an agenda, instructions for accessing the
virtual NCAB meetings, and any additional information for the
meetings will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-24578 Filed 11-6-23; 8:45 am]
BILLING CODE 4140-01-P
